One of today's notable stocks in decline is Keryx Biopharmaceuticals (NASDAQ:KERX), down 2.9% to $15.16. The S&P is currently trading 0.6% lower to 1,966 and the Dow Jones Industrial Average is trading 0.7% lower to 16,912.
In the past 52 weeks, shares of Keryx Biopharmaceuticals have traded between a low of $1.28 and a high of $17.46 and are now at $15.16, which is 1,084% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.6% while the 200-day MA has risen 0.4%.
Potential upside of 59.0% exists for Keryx Biopharmaceuticals, based on a current level of $15.16 and analysts' average consensus price target of $24.10. Keryx Biopharmaceuticals shares have support at the 50-day moving average (MA) of $14.07 and additional support at the 200-day MA of $13.60.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.